1-(4-methoxyphenyl)-4-aminopiperidine | 259663-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(4-methoxyphenyl)-4-aminopiperidine
• 英文别名: 1-(4-methoxyphenyl)piperidin-4-amine；1-(4-methoxy-phenyl)-piperidin-4-yl-amine
• CAS: 259663-88-2
• 化学式: C₁₂H₁₈N₂O
• mdl: MFCD08752981
• 分子量: 206.288
• InChiKey: LLQPZJOXQGVEEQ-UHFFFAOYSA-N

物化性质

• 沸点：
  352.9±37.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)-4-aminopiperidine 在 sodium hydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-[1-(4-methoxyphenyl)-4-piperidyl]-4-[(4-cyano-1-naphthyl)methylene]-piperidine
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r
• 作为产物：
  描述：

  1-(4-甲氧基苯基)哌啶-4-酮 在 盐酸羟胺 、 potassium carbonate 、 红铝 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 4.0h， 生成 1-(4-methoxyphenyl)-4-aminopiperidine
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r

文献信息

• Long-Lived Triplet State Charge Separation in Novel Piperidine-Bridged Donor−Acceptor Systems
  作者：Saskia I. van Dijk、Cornelis P. Groen、František Hartl、Albert M. Brouwer、Jan W. Verhoeven

  DOI：10.1021/ja960980g

  日期：1996.1.1

  photoexcitation of 3a in cyclohexane electron transfer occurs in the singlet manifold to afford the short-lived (τf = 0.75 ns) 1(D+−A-) state in ca. 70% yield. An important decay pathway of this D+−A- state consists of intersystem crossing (ISC) to yield a triplet state localized on the naphthalimide moiety (D−3A). In a slightly more polar solvent like di-n-butyl ether, an equilibrium between D−3A and

  提出了两个双发色系统，它们分别包含 N-烷基萘酰亚胺电子受体和 4-甲氧基苯胺 (3a) 或苯胺 (3b) 电子供体。在环己烷中电子转移中 3a 的光激发发生在单线态流形中，以提供大约 1 的短寿命（τf = 0.75 ns）1（D + -A-）状态。70% 的收率。这种 D+-A- 状态的一个重要衰变途径包括系统间交叉 (ISC)，以产生位于萘酰亚胺部分 (D-3A) 上的三重态。在极性稍强的溶剂（如二正丁基醚）中，通过瞬态吸收光谱观察到 D-3A 和 3(D+-A-) 之间的平衡。两个物种衰减的总衰减时间为大约。1 微秒。因此，在将 D+-A- 态的自旋多重性从单重态变为三重态时，观察到其寿命增加了三个数量级。在二恶烷、THF 和乙腈等极性更大的溶剂中，3(D+-A-) 态是在瞬态吸收光谱中观察到的唯一物质，十...
• Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0982026A2

  公开（公告）日：2000-03-01

  The present invention relates to the use of compounds of the general formula wherein Ar1is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide; Ar2is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen; Xis C, CH, C(OH) or N; Yis -CH2-, CH or O Z-CH2-, -CH(CH3)- or -C(CH3)2-; R1is hydrogen, lower alkyl or acetyl; Ais C=O or -(CHR2)n-, wherein R2 is hydrogen, lower alkyl or hydroxy-lower alkyl; Bis -(CH2)n-, O, -CH(OH)(CH2)n-, -CH(CH2OH)(CH2)n-, -(CH2)n CH(OH)- or -CH(CH2OH)-; ---may be a bond and nis 0-4 and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments which represent therapeutic indications for NMDA receptor subtype specific blockers.

  本发明涉及通式化合物的用途 式中 Ar1 是苯基、萘基或四氢萘基，可选择被羟基、低级烷氧基、硝基、氨基或甲磺酰胺取代； Ar2 是苯基、萘基或四氢萘基，可选择被低级烷基或卤素取代； X 是 C、CH、C(OH) 或 N； Y 是-CH2-、CH 或 O Z-CH2-、-CH(CH3)- 或 -C(CH3)2-； R1 是氢、低级烷基或乙酰基； A 是 C=O 或 -(CHR2)n-，其中 R2 是氢、低级烷基或羟基低级烷基； 双-(CH2)n-、O、-CH(OH)(CH2)n-、-CH(CH2OH)(CH2)n-、-(CH2)n CH(OH)-或-CH(CH2OH)-； ---可为键且 n 为 0-4 及其药学上可接受的酸加成盐，用于制造代表 NMDA 受体亚型特异性阻断剂治疗适应症的药物。
• [EN] AMIDINE AND GUANIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF<br/>[FR] DÉRIVÉS D'AMIDINE ET DE GAUNIDINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR APPLICATION MÉDICALE<br/>[ZH] 脒类和胍类衍生物、其制备方法及其在医药上的应用
  申请人：SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

  公开号：WO2019179362A1

  公开（公告）日：2019-09-26

  本发明公开了式(I-A)和(I-B)所示的脒类和胍类衍生物、其制备方法及其在医药上的应用，其用于预防、缓解和/或治疗由于免疫抑制而引起的疾病或病症。
• EP3575297
  申请人：——

  公开号：——

  公开（公告）日：——
• US6184236
  申请人：——

  公开号：——

  公开（公告）日：——